AIM

SEC Filing Summary: Hemispherx Biopharma, Inc. (10-K)

Business Context and Reporting Period

Company: Hemispherx Biopharma, Inc.
Filing Type: Annual Report on Form 10-K
Period Ended: December 31, 2008
Business Overview: A biopharmaceutical company focused on immune system enhancing technologies. The primary strategic focus is the clinical development of Ampligen(R) (poly I:poly C12U) for Chronic Fatigue Syndrome (CFS) and as a vaccine adjuvant. The company also holds the FDA-approved product Alferon N Injection(R) for genital warts, though commercial sales were halted in April 2008 due to inventory expiration.

Key Financial Metrics (Year Ended Dec 31, 2008)

Note: The company had no interest expense or debt in 2008, having retired all convertible debentures in June 2007.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues dropped 75% to $265,000. This was driven primarily by an 81% decrease in Alferon N Injection(R) sales ($173,000 vs. $925,000) due to the expiration of finished goods inventory in March 2008 and the subsequent halt of sales in April 2008. Ampligen(R) cost recovery sales also declined 32%.
• Reduced Net Loss: Net loss improved by 33% to $12.2 million. This improvement was largely due to a $4.6 million reduction in R&D expenses (as NDA preparation costs peaked in 2007) and a $2.5 million decrease in G&A expenses (driven by lower stock-based compensation and impairment charges).
• Cash Position: Cash and cash equivalents decreased by approximately $5.3 million to $6.1 million, reflecting a net cash outflow from operating activities of $9.4 million.

Guidance, Outlook, and Risks

• Ampligen(R) NDA Status: The FDA accepted the New Drug Application (NDA) for Ampligen(R) for CFS on July 7, 2008. The Prescription Drug User Fee Act (PDUFA) decision date was originally February 25, 2009, but was extended to May 25, 2009 to allow for a full review.
• Liquidity and Financing: Management estimates current funds ($6.1 million) are sufficient for approximately 16 months of operations. The company has a $30 million Common Stock Purchase Agreement with Fusion Capital Fund II, LLC, but sales are restricted if the stock price remains below $0.40 for 12 consecutive days. A Standby Financing Agreement for up to $1 million with executives was also entered into in February 2009.
• Cost Reduction Measures: Effective January 1, 2009, the company implemented a mandatory "Employee Wage Or Hours Reduction Program," requiring employees to accept wage reductions in exchange for stock incentives to conserve cash.
• Key Risks:
  • Regulatory Approval: No assurance that Ampligen(R) will receive FDA approval.
  • Product Availability: Alferon N Injection(R) sales are halted; production is on hold until mid-2009 pending funding and FDA facility inspections. Commercial availability may not resume until 2010.
  • Financing: Inability to raise additional capital could force the company to curtail operations or clinical trials.
  • Insurance: Product liability insurance was suspended in November 2008 to conserve cash, exposing the company to potential claims.

Investor Verification Checklist

• NDA Decision Date: Verify the status of the FDA review for Ampligen(R) and the May 25, 2009 PDUFA deadline.
• Alferon Inventory: Confirm the timeline for resuming production and commercial sales of Alferon N Injection(R) and the status of the FDA preapproval inspection at the New Brunswick facility.
• Cash Runway: Monitor the company's cash burn rate and the effectiveness of the wage reduction program in extending the 16-month liquidity runway.
• Stock Price Threshold: Track the common stock price relative to the $0.40 threshold required to activate the Fusion Capital financing agreement.
• Legal Proceedings: Review the status of the fraud claim against South African defendants (Bioclones) which was reinstated by the 11th Circuit Court of Appeals in December 2008.